BRGR.NS

BRGR.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.11, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.06, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints. In terms of profitability, BRGR.NS demonstrates a return on equity (ROE) of 19.18% and a return on assets (ROA) of 12.93%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is generating solid returns relative to its capital base, which is a positive sign for investors. The company's revenue is primarily concentrated in the production and sale of commodity chemicals, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation may expose the company to regional economic fluctuations, potentially increasing its operational risk. BRGR.NS has shown a consistent growth trajectory, with a free cash flow of 6,995.3 million INR and an operating cash flow of 12,690.5 million INR. These figures indicate the company's ability to generate cash from its operations, which can be reinvested or distributed to shareholders. The company's capital expenditure of -4,294.4 million INR suggests a reduction in capital spending, which may reflect a strategic shift or a response to market conditions. The risk assessment for BRGR.NS indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near future, which is favorable for existing shareholders. Recent events and filings for BRGR.NS include analyst estimates that provide a mean price target of 517.26 INR and a median price target of 520.00 INR. The mean recommendation from analysts is 3.00, indicating a neutral stance, with 2 strong-buy, 7 buy, and 5 hold recommendations. These analyst estimates suggest a generally positive outlook for the company's stock, although there is a range of opinions reflected in the high and low price targets.